Abstract
Objective To describe the design and implementation of state-level fertility preservation (FP) health insurance benefit mandates and regulation and to provide stakeholders with guidance on best practices, gaps, and implementation needs.
Design Legal mapping and implementation framework-guided analysis
Setting U.S. states with state-level fertility preservation health insurance benefit mandates
Patient(s) Individuals at risk of iatrogenic infertility
Intervention(s) State laws mandating health insurance benefit coverage for fertility preservation services.
Main Outcome Measure(s) Design features of FP mandated benefit legislation; implementation process
Result(s) Between June, 2017 and March, 2021, 11 states passed FP benefit mandate laws. On average, states took 223 days to implement their mandates from the start of the laws’ enactment dates to their corresponding effective dates, and a majority issued regulatory guidance after the law was in effect. Significant variation was observed in which FP services were specified for inclusion or exclusion in the laws and/or regulator guidance. Federal policies impacted state level implementation, with the ACA and HIPAA guiding design of fertility preservation benefits. In addition, a majority of states referenced medical society clinical practice guidelines in the design of FP mandated benefits.
Conclusions Our policy scan documented significant variation in the design and implementation of health insurance benefit mandates for FP services. Future considerations for policy development include specificity and flexibility of benefit design, reference to external clinical practice guidelines to drive benefit coverage, inclusion of Medicaid populations in required coverage, and consideration of interaction with relevant state and federal policies. In addition, key considerations for implementation include the sufficient length of time for the implementation period, regulator guidance issued prior to the law going into effect, and explicit allocation of resources for the implementation process.
Competing Interest Statement
HIS received speaking honorarium from Ferring Pharmaceutical
Funding Statement
UC San Diego Moores Cancer Center, Specialized Cancer Center Support Grant NIH/NCI P30CA023100 and UC San Diego Academic Senate pilot grant
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Research evaluated public programs and did not involve human subjects and thus was exempt from IRB review.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Capsule Variation was found among the design and implementation of 11 state-level fertility preservation health insurance mandates. Best practices for stakeholders to consider when designing and implementing benefit mandates are described.
Data Availability
The data that support the findings of this study are openly available via state legislature and insurance regulator websites
